Product
brolucizumab
Aliases
RTH258
3 clinical trials
3 indications
Indication
Macular Edema (DME)Indication
Age-Related Macular DegenerationClinical trial
OBservationaL stUdy to Evaluate Fluid reSolution and Effectiveness in Patients Receiving Beovu (Brolucizumab) Under KeY Treatment Schemes in Neovascular Age-related Macular Degeneration and Visual Impairment Due to Diabetic Macular EdemaStatus: Active (not recruiting), Estimated PCD: 2025-12-20
Clinical trial
A 56-week Phase IIIb/IV, Open-label, One-arm Extension Study to Assess the Efficacy and Safety of Brolucizumab 6 mg in a Treat-to-Control Regimen With Maximum Treatment Intervals up to 20 Weeks for the Treatment of Patients With Neovascular Age-related Macular Degeneration Who Have Completed the CRTH258A2303 (TALON) StudyStatus: Completed, Estimated PCD: 2023-03-28
Clinical trial
A Non-interventional Study to Assess the Influence of Automated Optical Coherence Tomography (OCT) Image Enrichment With Segmentation Information on Disease Activity Assessment in Patients Treated With Licensed Anti- VEGF InjectionsStatus: Completed, Estimated PCD: 2023-06-28